prr cancer vaccine - anzgog presentation, page-2

From the notes -

"Most advanced ovarian cancer vaccine in
development for maintenance: Cvac ™

• CVac is an autologous, dendritic-cell based therapy or
cancer vaccine targeting abnormal mucin-1
• Proven technology with FDA approval of Provenge ®
• Well tolerated in all studies to date
• Granted orphan product status by the U.S. FDA & EMA
– Additional several years of exclusivity and priority
regulatory treatment
• Phase I & Phase IIa trials are complete with promising
results
• Phase IIb is fully recruited and ongoing

CANcer VAccine Study (CANVAS

• 1000 patients, 800 evaluable
• Epithelial Ovarian Cancer: first remission
• Double Blind, Placebo Controlled
• Powered to demonstrate clinically significant
effect on PFS and OS (HR 0.77, p=0.049, 90%
power
• 22 countries, 120 investigative sites
• Australia is a key country for recruitment
• First patients already enrolled in the US

Summary

• Malignant tumours evolve to fool the immune
system
• Re-education of the immune system may be an
effective modality
• Vaccines are in clinical development for ovarian
cancer
• Vaccine therapy will complement existing
approaches
• Vaccines could mean better quality of life and
longer survival for our patients "

I like the bit included by no coincidence " • First patients already enrolled in the US "

... becuase we are now catering to a US audience